SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 218 filers reported holding SAGE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $794 | -48.9% | 16,892 | -54.4% | 0.01% | -63.2% |
| Q1 2023 | $1,555 | +98.6% | 37,072 | +80.4% | 0.02% | +72.7% |
| Q4 2022 | $783 | -99.9% | 20,550 | +50.4% | 0.01% | +83.3% |
| Q3 2022 | $535,000 | -16.3% | 13,665 | -29.3% | 0.01% | +20.0% |
| Q1 2022 | $639,000 | -38.9% | 19,319 | -21.4% | 0.01% | -16.7% |
| Q4 2021 | $1,045,000 | -6.9% | 24,574 | -3.0% | 0.01% | -14.3% |
| Q3 2021 | $1,123,000 | +41.1% | 25,346 | +138.2% | 0.01% | -12.5% |
| Q1 2021 | $796,000 | +20.4% | 10,640 | +39.0% | 0.01% | -38.5% |
| Q4 2020 | $661,000 | -62.4% | 7,652 | -73.4% | 0.01% | -74.5% |
| Q3 2020 | $1,758,000 | +173.0% | 28,765 | +85.5% | 0.05% | +168.4% |
| Q2 2020 | $644,000 | +106.4% | 15,503 | +595.8% | 0.02% | +26.7% |
| Q3 2019 | $312,000 | -37.6% | 2,228 | -30.4% | 0.02% | -91.8% |
| Q2 2018 | $500,000 | – | 3,200 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |